文献速递区域麻醉与超声疼痛医学

神经周围右美托咪定增强臂丛神经阻滞质量的证据基础:随机对照试验的系统综述与Meta分析

Evidence basis for using perineural dexmedetomidine to enhance the quality of brachial plexus nerve blocks: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Br J Anaesth · 2017-01-01

该系统综述与Meta分析纳入32项随机对照试验共2007例患者,评估神经周围右美托咪定作为局麻药佐剂在臂丛神经阻滞中的效果。结果显示右美托咪定可延长感觉、运动阻滞及镇痛持续时间,加快阻滞起效,减少术后口服吗啡消耗量并提高满意度,但增加心动过缓和低血压风险。

要点

  • 神经周围右美托咪定可延长臂丛神经阻滞感觉、运动及镇痛持续时间并加快起效。
  • 右美托咪定减少术后口服吗啡消耗量10.2mg并改善疼痛控制和满意度。
  • 需权衡运动阻滞延长及一过性心动过缓、低血压风险,50-60µg剂量可能优化获益风险比。

核心结论

  • 新证据表明神经周围右美托咪定可改善臂丛神经阻滞的起效、质量和镇痛效果。
  • 但获益需与运动阻滞延长及一过性心动过缓和低血压风险权衡。

研究设计与样本

  • 系统综述与Meta分析,纳入32项随机对照试验共2007例患者。
  • 比较右美托咪定加入局麻药与单用局麻药在臂丛神经阻滞中的效果。
  • 采用随机效应模型分析,连续结局使用均值比(下限置信区间[点估计])表示。

主要发现

  • 右美托咪定延长感觉阻滞至少57%(P < 0.0001)、运动阻滞至少58%(P < 0.0001)及镇痛至少63%(P < 0.0001)持续时间。
  • 右美托咪定加快感觉阻滞起效至少40%(P < 0.0001)和运动阻滞起效至少39%(P < 0.0001)。
  • 右美托咪定减少术后口服吗啡消耗量10.2mg [-15.3, -5.2](P < 0.0001),改善疼痛控制并提高满意度。
  • 右美托咪定增加心动过缓(3.3 [0.8, 13.5],P = 0.0002)和低血压(5.4 [2.7, 11.0],P < 0.0001)的比值比。
  • 50-60µg右美托咪定剂量在最大化感觉阻滞持续时间的同时最小化血流动力学副作用,无患者出现神经后遗症。

关键数值与推荐

  • 感觉阻滞证据质量根据GRADE系统为高。
  • 50-60µg右美托咪定剂量可能优化感觉阻滞持续时间与血流动力学副作用之间的平衡。

临床怎么用

  • 可考虑在臂丛神经阻滞中加用右美托咪定以改善阻滞起效、质量和镇痛。
  • 使用时应监测并警惕心动过缓和低血压,尤其注意剂量选择。

局限性

  • 运动阻滞延长的风险需与获益权衡。
  • 一过性心动过缓和低血压风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dexmedetomidine has been proposed as a perineural local anaesthetic (LA) adjunct to prolong peripheral nerve block duration; however, results from our previous meta-analysis in the setting of brachial plexus block (BPB) did not support its use. Many additional randomized trials have since been published. We thus conducted an updated meta-analysis. METHODS: Randomized trials investigating the addition of dexmedetomidine to LA compared with LA alone (Control) in BPB for upper extremity surgery were sought. Sensory and motor block duration, onset times, duration of analgesia, analgesic consumption, pain severity, patient satisfaction, and dexmedetomidine-related side-effects were analysed using random-effects modeling. We used ratio-of-means (lower confidence interval [point estimate]) for continuous outcomes. RESULTS: We identified 32 trials (2007 patients), and found that dexmedetomidine prolonged sensory block (at least 57%, P < 0.0001), motor block (at least 58%, P < 0.0001), and analgesia (at least 63%, P < 0.0001) duration. Dexmedetomidine expedited onset for both sensory (at least 40%, P < 0.0001) and motor (at least 39%, P < 0.0001) blocks. Dexmedetomidine also reduced postoperative oral morphine consumption by 10.2mg [-15.3, -5.2] (P < 0.0001), improved pain control, and enhanced satisfaction. In contrast, dexmedetomidine increased odds of bradycardia (3.3 [0.8, 13.5](P = 0.0002)), and hypotension (5.4 [2.7, 11.0] (P < 0.0001)). A 50-60µg dexmedetomidine dose maximized sensory block duration while minimizing haemodynamic side-effects. No patients experienced any neurologic sequelae. Evidence quality for sensory block was high according to the GRADE system. CONCLUSIONS: New evidence now indicates that perineural dexmedetomidine improves BPB onset, quality, and analgesia. However, these benefits should be weighed against increased risks of motor block prolongation and transient bradycardia and hypotension.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Vorobeichik L, Brull R, Abdallah FW, et al. Evidence basis for using perineural dexmedetomidine to enhance the quality of brachial plexus nerve blocks: a systematic review and meta-analysis of randomized controlled trials. Br J Anaesth. 2017. PMID: 28100520. doi:10.1093/bja/aew411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。